D. E. Shaw & Co., Inc. Oramed Pharmaceuticals Inc. Transaction History

D. E. Shaw & Co., Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.07 - $2.83 $66,107 - $90,378	-31,936 Reduced 45.3%	38,566 $99,000
Q1 2024 May 15, 2024	BUY	$2.18 - $3.58 $24,921 - $40,926	11,432 Added 19.35%	70,502 $205,000
Q4 2023 Feb 14, 2024	BUY	$1.71 - $2.57 $101,009 - $151,809	59,070 New	59,070 $136,000
Q2 2022 Aug 15, 2022	SELL	$3.72 - $9.0 $51,127 - $123,696	-13,744 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$8.19 - $13.89 $1.32 Million - $2.24 Million	-161,051 Reduced 92.14%	13,744 $119,000
Q4 2021 Feb 14, 2022	BUY	$12.98 - $29.75 $2.27 Million - $5.2 Million	174,795 New	174,795 $2.5 Million

7.4M

2.1K

Ticker ORMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,100
Market Cap $92M
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.